Rodent models for human diseases.

One of the factors limiting the translation of knowledge from preclinical studies to the clinic has been the limitations of in vivo diseases models. Except in the case of highly controlled and regulated clinical trials, geneticists and scientists do not use humans for their experimental investigations because of the obvious risk to life. Instead, they use various animal, fungal, bacterial, and plant species as model organisms for their studies. Amongst these model organisms, rodent models are the most used due to the easiness for the experiments and the possibility to modify genetically these model animals. Nevertheless, due to the fact that animal models typically do not contract the same genetic diseases as people, so scientists must alter their genomes to induce human disease states and to know what kind of mutation causes the disease. In this brief review, we will discuss the interests of rodent models that have been developed to simulate human pathologies, focusing in models that employ xenografts and genetic modification. Within the framework of genetically engineered mouse (GEM) models, we will review some of the current genetic strategies for modeling diseases.

[1]  M. Hoekstra,et al.  Mouse models of disturbed HDL metabolism. , 2015, Handbook of experimental pharmacology.

[2]  A. Richmond,et al.  Mouse xenograft models vs GEM models for human cancer therapeutics , 2008, Disease Models & Mechanisms.

[3]  F. Ruddle,et al.  Integration and stable germ line transmission of genes injected into mouse pronuclei. , 1981, Science.

[4]  Q. Lian,et al.  Regulation of 11beta-hydroxysteroid dehydrogenase 1 and 2 by IGF-1 in mice. , 2010, Biochemical and biophysical research communications.

[5]  Peter J Houghton,et al.  Establishment of human tumor xenografts in immunodeficient mice , 2007, Nature Protocols.

[6]  R. Cardiff,et al.  Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. , 2005, Cancer research.

[7]  B. Connolly,et al.  Non-Invasive Bioluminescence Imaging of β-Cell Function in Obese-Hyperglycemic [ob/ob] Mice , 2014, PloS one.

[8]  Y. Shinoda,et al.  Mouse Models of Mutations and Variations in Autism Spectrum Disorder-Associated Genes: Mice Expressing Caps2/Cadps2 Copy Number and Alternative Splicing Variants , 2013, International journal of environmental research and public health.

[9]  F. Costantini,et al.  Introduction of a rabbit β-globin gene into the mouse germ line , 1981, Nature.

[10]  K. Kuo,et al.  Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. , 2010, Journal of the American College of Cardiology.

[11]  F H Ruddle,et al.  Genetic transformation of mouse embryos by microinjection of purified DNA. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Markus G. Manz,et al.  Development of a Human Adaptive Immune System in Cord Blood Cell-Transplanted Mice , 2004, Science.

[13]  M. Kotb,et al.  Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2Rγnull Mice Engrafted with Mobilized Human Hemopoietic Stem Cells 12 , 2004, The Journal of Immunology.

[14]  V. Ntziachristos,et al.  Multimodal Molecular Imaging of Integrin αvβ3 for In Vivo Detection of Pancreatic Cancer , 2014, The Journal of Nuclear Medicine.

[15]  Zhengxin Wang,et al.  Modulation of androgen receptor‐dependent transcription by resveratrol and genistein in prostate cancer cells , 2004, The Prostate.

[16]  T. Graeber,et al.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors. , 2003, Cancer cell.

[17]  R. Palmiter,et al.  Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs , 1981, Cell.

[18]  R. Jaenisch,et al.  Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Cardiff,et al.  Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. , 2003, Cancer research.

[20]  K. Korach,et al.  Estrogen hormone physiology: reproductive findings from estrogen receptor mutant mice. , 2014, Reproductive biology.

[21]  Douglas Hanahan,et al.  The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. , 2007, Genes & development.

[22]  M. Capecchi,et al.  Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells , 1987, Cell.

[23]  A. Samarel,et al.  Cardiomyocyte-specific expression of CRNK, the C-terminal domain of PYK2, maintains ventricular function and slows ventricular remodeling in a mouse model of dilated cardiomyopathy. , 2014, Journal of molecular and cellular cardiology.

[24]  Todd R. Golub,et al.  Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Chambon,et al.  Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma , 2008, Proceedings of the National Academy of Sciences.

[26]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Wei Chen,et al.  Genetically Engineered Lactococcus lactis Protect against House Dust Mite Allergy in a BALB/c Mouse Model , 2014, PloS one.

[28]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[29]  R. Cardiff,et al.  Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. , 2002, Cancer research.

[30]  H. Shimokawa,et al.  Nitric oxide synthases and heart failure - lessons from genetically manipulated mice. , 2013, Journal of UOEH.

[31]  P. Pandolfi,et al.  Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse , 2001, Nature Genetics.

[32]  P. Pandolfi,et al.  Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.

[33]  M. Sykes,et al.  CD4 T Cell-Mediated Alloresistance to Fully MHC-Mismatched Allogeneic Bone Marrow Engraftment Is Dependent on CD40-CD40 Ligand Interactions, and Lasting T Cell Tolerance Is Induced by Bone Marrow Transplantation with Initial Blockade of this Pathway1 , 2001, The Journal of Immunology.

[34]  R. Cardiff,et al.  Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[36]  V. Fendrich,et al.  Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. , 2013, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[37]  C. Cordon-Cardo,et al.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  K. Ando,et al.  A highly sensitive strategy for SCID-repopulating cell assay by direct injection of primitive human hematopoietic cells into NOD/SCID mice bone marrow. , 2003, Blood.

[39]  H. Guillou,et al.  P-glycoprotein Dysfunction Contributes to Hepatic Steatosis and Obesity in Mice , 2011, PloS one.

[40]  R. Schiestl,et al.  IL-13 overexpression in mouse lungs triggers systemic genotoxicity in peripheral blood. , 2014, Mutation research.

[41]  K. Kadomatsu,et al.  Neuroblastoma models for insights into tumorigenesis and new therapies , 2015, Expert opinion on drug discovery.

[42]  C. Sander,et al.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis , 2009, Nature Genetics.

[43]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[44]  L. Chin,et al.  BRAF Activation Initiates but Does Not Maintain Invasive Prostate Adenocarcinoma , 2008, PloS one.

[45]  K. Kretschmer,et al.  Foxp3+ Regulatory T Cells in Mouse Models of Type 1 Diabetes , 2013, Journal of diabetes research.

[46]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[47]  P. Chaurand,et al.  A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. , 2001, Cancer research.

[48]  K. Akashi,et al.  Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice , 2005 .

[49]  Peter A. Humphrey,et al.  Conditional Loss of Nkx3.1 in Adult Mice Induces Prostatic Intraepithelial Neoplasia , 2002, Molecular and Cellular Biology.

[50]  Manuel Desco,et al.  K-RasV14I recapitulates Noonan syndrome in mice , 2014, Proceedings of the National Academy of Sciences.